Newsroom
The Latest News From the Ivy Center
The Ivy Brain Tumor Center at Barrow Neurological Institute strives to be a valuable resource for any brain tumor or brain cancer-related media needs. Our media relations team is happy to help answer questions and arrange interviews. The expert neurosurgeons, neuro-oncologists and scientists at the Ivy Center are available to speak on a variety of topics.
Our state-of-the-art media studio is available for audio and video interviews. We can also arrange filming opportunities at various locations around the center and labs.
To contact the media relation team, call Jennifer Keeler at 602-670-4400 or email: [email protected].
Please see below for the latest media coverage and news from the Ivy Center. To read about our inspiring patients and those behind the scenes at the Ivy Center, visit the Ivy Blog.
ASCO24: A roundup of the latest data from Merus, MorphoSys and others
Endpoints News featured The Ivy Brain Tumor Center’s Phase 0/2 study of niraparib, GSK’s PARP inhibitor, in newly diagnosed glioblastoma patients. This study had promising results and has led the Ivy Brain Tumor Center and GSK to collaborate on a Phase 3 study of niraparib versus temozolomide in MGMT-unmethylated glioblastoma. Read more!
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
The Ivy Brain Tumor Center has released promising Phase 0/2 clinical trial results for niraparib, showing a significant improvement in overall survival for newly diagnosed glioblastoma patients, with survival times nearly doubling to 20.3 months compared to standard care. These findings will be presented at the 2024 ASCO Annual Meeting. Encouraged by these results, GSK is supporting the initiation of a global Phase 3 trial to further evaluate niraparib versus standard care.
‘Dine & Donate’ supports brain tumor research across Phoenix-area
Good Morning Arizona spotlighted the Ivy Brain Tumor Center at Barrow Neurological Institute in recognition of Brain Tumor Awareness Month. As part of this initiative, Cold Beer and Cheeseburgers has teamed up with the Ivy Center for their annual Dine & Donate campaign. This partnership plays a crucial role in advancing vital research efforts aimed at combating brain tumors. Learn more about how you can support this important cause.
2024 Health-Care Heroes
Phoenix Magazine has recognized Jacki Garcia, Nurse Educator at the Ivy Brain Tumor Center, as a 2024 Healthcare Hero. Jacki has played a crucial role in supporting our brain tumor patients through their brain cancer journeys with profound compassion and empathy.
AstraZeneca’s ATM Inhibitor, Radiation Show Encouraging Signals in Two Early Brain Cancer Trials
Precision Medicine Online's article covered the Ivy Center's groundbreaking findings at the American Association for Cancer Research's annual meeting. Dr. Sanai's Phase 0/1 trial demonstrated the efficacy of AstraZeneca's AZD1390 in treating glioblastoma. These findings offer new hope for patients with limited treatment options. Learn more!
AstraZeneca’s ‘radiosensitizer’ may enhance efficacy of radiation for deadly brain cancer: #AACR24
Endpoints News highlighted Dr. Nader Sanai’s groundbreaking research with AstraZeneca's AZD1390 in glioblastoma treatment at AACR 2024. The Phase 0 study, led by Dr. Sanai, Director of the Ivy Brain Tumor Center, demonstrates the drug's efficacy in penetrating brain tissue—a pivotal advancement in glioblastoma therapy. Learn more!
AACR Annual Meeting 2024: The key announcements you need to read
Biopharma Reporter featured the Ivy Brain Tumor Center's presentation at the AACR Annual Meeting 2024, where groundbreaking advancements in glioblastoma research were highlighted. The Ivy Center unveiled promising results from their clinical trials, particularly the potential of AZD1390 as an effective radiosensitizer for treating recurrent glioblastoma.
Ivy Brain Tumor Center Announces Promising Results of Phase 0/1 Glioblastoma Study at the American Association for Cancer Research Annual Meeting
The Ivy Brain Tumor Center announced initial results from a Phase 0/1b clinical trial of AZD1390, in combination with radiation therapy, in newly diagnosed, MGMT-unmethylated glioblastoma. Results from this study will be presented at the American Association for Cancer Research Annual Meeting and demonstrate that AZD1390 may be a potent radiosensitizer in both newly diagnosed and recurrent glioblastoma patients. Read the press release to learn more.
Ivy Brain Tumor Center Announces Promising Results of Phase 0/1 Glioblastoma Study at the American Association for Cancer Research Annual Meeting
AZBio spotlighted Dr. Nader Sanai's presentation at the American Association for Cancer Research Annual Meeting, where the Ivy Brain Tumor Center revealed promising results from a Phase 0/1b clinical trial of AZD1390 combined with radiation therapy for newly diagnosed, MGMT-unmethylated glioblastoma. These findings indicate that AZD1390, an ATM kinase inhibitor, enhances radiation therapy by preventing acute DNA damage repair. Read the full story!
Ivy Brain Tumor Center Awarded U.S. Department of Defense Grant to Advance Promising Glioblastoma Drug Candidate
The Ivy Brain Tumor Center received a $1.48 million, three-year U.S. Department of Defense (DoD) Impact Award to advance the development of MnP3. This novel redox-active agent shows potential in the treatment of glioblastoma. Successful completion of the project will have a significant impact on translating the drug to clinical use.